From: Ovarian cancer immunotherapy: opportunities, progresses and challenges
Strategies | Pros | Cons |
---|---|---|
Antibody-based vaccine | Tumor antigen specific. Easy to produce. | Weak immunogenicity. Not for all individuals. |
Peptide vaccine | Safe, stable, and easy to produce and modify. | Poor immunogenicity. HLA restriction. |
Cytokine vaccine | Easy to manufacture and administer. | Non-specific immunomodulating only. |
Tumor cell vaccine | Convenience, contained tumor antigen pool. | Potential safety concern. Difficult to produce. Difficult to standardize. |
Dendritic cell vaccine | Powerful professional antigen presenting cells. May prime both T cells and antibody response. | Difficult to manufacture and standardize. |
HSP vaccine | May contain multiple antigens. | Difficult to manufacture and standardize. |
Immunomodulation with Treg blockage | Promising strategy | No data on ovarian cancer yet Difficult to completely eliminate Treg. |